of uncovered stents, it was not possible to place covered stents within them. Thus, we decided to insert the Hemospray cannula inside the left stent, up to the hilum, and spray the powder while withdrawing the cannula down to the papilla (Video 1, available online at www.VideoGIE. org). Active bleeding stopped thereafter, and the patient did not experience immediate adverse events. The patient remained asymptomatic after the procedure, and follow-up examinations showed a rise of the hemoglobin level, whereas the bilirubin value remained just above normal (1.41 mg/dL). Because no curative options could be offered to the patient, she was discharged 16 days later.
To our knowledge, this is the first reported case of hemostatic powder used to treat a malignant intraductal bleeding, which was successful without any major adverse events. Reasons of concern about the safety of this procedure are the impossibility of obtaining a direct view of the bleeding site and of targeting the powder application. Therefore, the risk of biliary obstruction cannot be ruled out completely. However, in an acute setting with a patient in unstable condition, where other treatment options are not feasible, this could be considered a valuable rescue procedure.
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